Codexis, Inc. (CDXS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Redwood City, CA, United States. The current CEO is Alison Moore.
CDXS has IPO date of 2010-04-22, 188 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $215.36M.
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
